黄芪多糖在支气管哮喘中的免疫调节作用和相关机制的研究进展
陈曦 施京红 吴守振
陕西中医药大学医学技术学院,陕西咸阳 712046
Research progress on the immune regulation function and mechanism of astragalus polysaccharides in bronchial asthma
CHEN Xi SHI Jinghong WU Shouzhen
College of Medical Technology, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712046, China
摘要 免疫细胞失衡及其诱发的细胞因子“风暴”是支气管哮喘(以下简称“哮喘”)发生和急性发作的主要驱动因素,调节免疫细胞失衡及细胞因子“风暴”是哮喘治疗的根本。中药及其组分具有免疫调节功能,可通过多种途径维持体内免疫平衡。黄芪多糖是中药黄芪的活性成分,具有抗炎和免疫调节功能。本文从黄芪多糖相互作用的受体出发,综述了其调节MAPK和NF-κB信号通路的分子机制,全面总结了其在哮喘中的免疫调节作用和机制,为黄芪多糖在哮喘防治的临床应用中提供了理论基础,也为中药黄芪的现代研究提供了分子基础。
关键词 :
支气管哮喘 ,
黄芪多糖 ,
免疫调节 ,
机制 ,
中医
Abstract :The imbalance of immune cells and the cytokine “storm” it induces are the main driving factors for the occurrence and acute attack of bronchial asthma(“asthma” for short), and the regulation of immune cell imbalance and cytokine“storm” is the fundamental treatment of asthma. Traditional Chinese medicine and its components have immune regulatory functions and can maintain the immune balance in vivo through various ways. Astragalus polysaccharides is the active ingredient of traditional Chinese medicine Huangqi, which has anti-inflammatory and immunomodulatory functions. Based on the interaction of astragalus polysaccharides receptors, this paper reviewed the molecular mechanisms of astragalus polysaccharides regulating MAPK and NF-κB signaling pathways, and comprehensively summarized its immunomodulatory effects and mechanisms in asthma, providing a theoretical basis for the clinical application of astragalus polysaccharides in asthma prevention and treatment, as well as a molecular basis for modern research on traditional Chinese medicine Huangqi.
Key words :
Bronchial asthma
Astragalus polysaccharides
Immune regulation
Mechamism
Traditional Chinese medicine
基金资助: 陕西省科技厅重点研发计划项目(2022SF-093); 陕西省西安市卫生健康委员会面上培育项目(2020ms10)。
通讯作者:
吴守振(1979.3-),男,博士,研究员,硕士生导师;研究方向:中西医结合基础。
作者简介 : 陈曦(1999.10-),女,陕西中医药大学医学技术学院2022级中西医结合基础专业在读硕士研究生;研究方向:中西医结合基础。
[1] Zheng Y,Ren W,Zhang L,et al. A Review of the Pharmacological Action of Astragalus Polysaccharide [J]. Front Pharmacol,2020,11:349. [2] Zhang J,Feng QS. Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease [J]. Front Pharmacol,2022,13:854674. [3] Zhou LJ,Liu ZJ,Wang ZX,et al. Astragalus polysaccharides exerts immunomodulatory effects via TLR4-mediated MyD88- dependent signaling pathway in vitro and in vivo [J]. Scientific Reports,2017,7:44822. [4] Yang J,Qin L,Huang J,et al. Astragalus polysaccharide atten- uates LPS-related inflammatory osteolysis by suppressing osteoclastogenesis by reducing the MAPK signalling pathway [J]. J Cell Mol Med,2021,25(14):6800-6814. [5] Yue JC,José ML. Understanding MAPK Signaling Pathways in Apoptosis [J]. In J Mole Sci,2020,21(7):2346. [6] Grave N,Scheffel TB,Cruz FF,et al. The functional role of p38 MAPK pathway in malignant brain tumors [J]. Front Phar- macol,2022,13:975197. [7] Dong N,Li X,Xue C,et al. Astragalus polysaccharides alleviates LPS-induced inflammation via the NF-κB/MAPK signaling pathway [J]. J Cell Physiol,2020,235(7/8):5525- 5540. [8] 王金磊,李承德,孙宏伟,等.黄芪多糖抑制NF-κB/MAPK信号通路和改善哮喘大鼠气道炎症的作用[J].中国药理学通报,2016,32(4):489-493. [9] Feng S,Ding H,Liu L,et al. Astragalus polysaccharide enhances the immune function of RAW264.7 macrophages via the NF-κB p65/MAPK signaling pathway [J]. Exp Ther Med, 2021,21(1):20. [10] Zhang R,Xu L,An X,et al. Astragalus polysaccharides attenuate pulmonary fibrosis by inhibiting the epithelial- mesenchymal transition and NF-κB pathway activation [J]. Int J Mol Med,2020,46(1):331-339. [11] Xu J,Zhang Q,Li Z,et al. Astragalus Polysaccharides Attenuate Ovalbumin-Induced Allergic Rhinitis in Rats by Inhibiting NLRP3 Inflammasome Activation and NOD2- Mediated NF-κB Activation [J]. J Med Food,2021,24(1):1-9. [12] He X,Liu L,Luo X,et al. Astragalus Polysaccharide Relieves Inflammatory Responses in Guinea Pigs with Allergic Rhinitis via Ameliorating NF-κB-Mediated Treg/Th17 Imbalance [J]. Am J Rhinol Allergy,2022,36(5):638-648. [13] 孔一卜,孙丽平.中药调控NF-κB信号通路治疗哮喘作用机制的研究进展[J].中国中医基础医学杂志,2020,26(6):862-866. [14] León B,Ballesteros-Tato A. Modulating Th2 Cell Immunity for the Treatment of Asthma [J]. Front Immunol,2021,12:637948. [15] 张浩.黄芪多糖注射液对支气管哮喘患者肺泡灌洗液炎症因子及T细胞亚群的影响[J].河北医学,2017,23(3):480-483. [16] Chang Y,Al-Alwan L,Risse P A,et al. Th17-associated cytokines promote human airway smooth muscle cell proliferation [J]. FASEB J,2012,26(12):5152-5160. [17] Zhao J,Lloyd CM,Noble A. Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling [J]. Mucosal Immunology,2013,6(2):335-346. [18] 余涛,喻强强,丁明,等.基于Th17/Treg免疫失衡的益气温阳护卫法防治哮喘作用机制初探[J].时珍国医国药,2020,31(3):654-656. [19] Lin J,Kang H,Liang J,et al. CpG oligonucleotides and Astragalus polysaccharides are effective adjuvants in cultures of avian bone-marrow-derived dendritic cells [J]. Br Poult Sci,2015,56(1):30-38. [20] 商玉立,郭彩霞,石红梅,等.黄芪多糖对哮喘小鼠气道炎症启动因子TSLP和DCs表达的影响[J].中国抗生素杂志,2021,46(7):711-716. [21] 刘璟,游进.黄芪多糖在变应性哮喘大鼠模型中对树突状细胞的免疫干预作用[J].中国生物制品学杂志,2018,31(2):140-144. [22] 鲁蓉,王昊,王福玲,等.APS治疗CVA模型小鼠的效果评价[J].哈尔滨商业大学学报(自然科学版),2020, 36(4):410-413. [23] 朱学懿,魏颖,董竞成.黄芪治疗支气管哮喘的药理作用研究述评[J].中国中医基础医学杂志,2021,27(1):182- 185. [24] 王杜娟,王福玲,杨海娇,等.MS联合APS治疗CVA模型小鼠的效果评价[J].黑龙江医药,2022,35(1):5-7. [25] 邱镞文,高伟,吴炬,等.黄芪多糖注射液对哮喘患者支气管灌洗液或痰液炎症细胞计数和相关因子水平的影响[J].解放军预防医学杂志,2018,36(6):746-749. [26] 常兴,张庆祥,刘燕,等.基于“肺阳虚”理论探析温阳化饮方对哮喘寒饮蕴肺证细胞自噬的作用机制[J].中华中医药杂志,2020,35(2):650-654. [27] 王利红,张影,兰坤,等.黄芪多糖对哮喘模型小鼠肺组织炎症的抑制作用及其机制[J].吉林大学学报(医学版),2019,45(2):313-318. [28] 李培培,曾军,冯晓丽,等.黄芪多糖注射液对哮喘患者的影响[J].实用心脑肺血管病杂志,2018,26(1):130-132. [29] 李杨,杨玲玲,白彦丽,等.黄芪多糖对支气管哮喘模型小鼠气道炎症及水通道蛋白5表达的影响[J].甘肃中医药大学学报,2018,35(3):16-20. [30] 闫伟华,常静侠.黄芪多糖对哮喘大鼠气道炎症及肺组织血管内皮生长因子表达的影响[J].中国临床药理学杂志,2020,36(8):953-955.
[1]
孙宜斌1 朱铭星2 刘跃洋3 赵若玮1 黄鸣清1 程再兴1 郑燕芳1 林彦翔1. 中药抗肝损伤机制的研究进展 [J]. 中国医药导报, 2023, 20(9): 38-40,45.
[2]
朱晓娴1 陈慧芝1 崔奎琰1 钟文2 彭新生1 周郁斌1. 外泌体在肿瘤诊断和治疗中的应用现状与展望 [J]. 中国医药导报, 2023, 20(9): 41-45.
[3]
徐静雯1 琚沅红2 王书童1 吕淑贞1 牟冬梅2. 基于古今医案的中医辨治中风规律研究 [J]. 中国医药导报, 2023, 20(9): 109-113.
[4]
秦培洁 刘谦 王柳青 安宏 石雪芹 王诗恒 刘剑锋. 从中医药传统知识保护看民间中医药的传承发展 [J]. 中国医药导报, 2023, 20(9): 127-130.
[5]
许继升1 宋爱莉2 浦冬青1 王静1 张靖誉1 时光喜2 李静蔚2. 名老中医宋爱莉治疗乳腺癌骨转移用药规律分析 [J]. 中国医药导报, 2023, 20(9): 131-134,143.
[6]
杨光奕1 王珊珊2 张思洁2 白冰2. 《千金要方》英文节译本评述 [J]. 中国医药导报, 2023, 20(9): 139-143.
[7]
张思. 中医情志护理结合精细化护理对乳腺癌术后患者自我效能及生存质量的影响 [J]. 中国医药导报, 2023, 20(9): 156-159.
[8]
程芳1 胡坤敏1 朱珊2. 活血化瘀类中药抗炎机制研究进展 [J]. 中国医药导报, 2023, 20(8): 46-49,65.
[9]
邹吉轩1 赵霈1 宋英2 曹新甜1 王明镜2 刘为易2 吕妍2 胡晓梅2. 从命门水火学说探讨左归丸、右归丸对免疫系统的调节作用 [J]. 中国医药导报, 2023, 20(8): 137-140,145.
[10]
王柳青1 刘谦1 张震2 安宏1 秦培洁1 石雪芹1 张凤霞1 刘剑锋1. 中医药传统知识保护概念析要 [J]. 中国医药导报, 2023, 20(8): 146-149.
[11]
王豪楠 韩永谦 董燚菲 陈志艳 陈倩 李咏梅. 经颅磁刺激在中枢神经病理性疼痛中的应用研究进展 [J]. 中国医药导报, 2023, 20(7): 54-58.
[12]
魏德健 张梦秋 刘静 曹慧 马金刚. 中医药院校智能医学工程专业建设路径探索 [J]. 中国医药导报, 2023, 20(7): 73-76.
[13]
冯佳琪1 张丽丽2 王丽2 曹正民2 吕文良2. 姚乃礼教授基于“通其道”辨治失眠的经验 [J]. 中国医药导报, 2023, 20(7): 139-142.
[14]
张冰晗1 马科党2 陶春艳1 韩世荣2 李文彬2. 基于数据挖掘平台的韩世荣名老中医治疗白癜风的用药规律研究 [J]. 中国医药导报, 2023, 20(7): 148-151,168.
[15]
刘娅 王海腾 房纬. 中医药疗法治疗紧张性头痛有效性的网状meta分析 [J]. 中国医药导报, 2023, 20(7): 135-138.